BridgeMD
Phase 1/2 multicenter, open-label, dose-escalation study of IDP-121 in patients with relapsed/refractory hematologic malignancies (CASSANDRA)
EU CTIS ID: 2024-519194-19-00
What this study is testing
Dose-Escalation Phase (Phase 1): To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), B-cell lymphoma, and chronic lymphocytic leukemia (CLL). Expansion Phase (Phase 2): To evaluate the overall response rate (ORR) in patients with MM, B-cell lymphoma or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).
- Phase I and Phase II (Integrated)- First administration to humans
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age ≥18 years
- Performance status (ECOG) ≤ 2
- Life expectancy ≥3 months
- Patient is, in the investigator’s opinion, willing and able to comply with the protocol requirements.
- Patient has given voluntary written informed consent before performance of any studyrelated procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- Patients diagnosed with chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma (MM) who are ineligible to receive the available treatments.
You likely can't join if
- Persistent clinically significant non-hematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade <2 symptomatic peripheral neuropathy is allowed.
- The patient is known to be human immunodeficiency virus (HIV) positive, unless the patient is on antiviral therapy with HIV RNA levels <50 copies/mL; Hepatitis B surface antigen-positive or active hepatitis C infection, unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels; or active CMV infection (IgM positive).
- Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1.
- Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment
- Limitation of the patient’s ability to comply with the treatment or follow-up protocol.
- If a COVID-19 vaccine is administered, it should be done >72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase”).
See the full eligibility criteria
Who can join
- Age ≥18 years
- Performance status (ECOG) ≤ 2
- Life expectancy ≥3 months
- Patient is, in the investigator’s opinion, willing and able to comply with the protocol requirements.
- Patient has given voluntary written informed consent before performance of any studyrelated procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care.
- Patients diagnosed with chronic lymphocytic leukemia (CLL), B-cell lymphomas, and multiple myeloma (MM) who are ineligible to receive the available treatments.
- Adequate hematological or biochemical parameters as specified below a. Hemoglobin > 8.0 g/dl (without transfusion support within 7 days) b. Platelets count > 75 x109/L (without transfusional support within 7 days). In patients with bone marrow infiltration, the platelets count may be ≥50 x109/L. c. Absolute neutrophil count (ANC) > 0.75 x109/L (without G-CSF support within 7 days) d. Aspartate transaminase (AST): <2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases) e. Alanine transaminase (ALT): < 2.5 x the upper limit range (in patients with no liver metastases or <5 x ULN in patients with liver metastases) f. Total bilirubin: < 2 x the upper limit range. g. Calculated or measured creatinine clearance: >30 mL/min (calculated from the Cockcroft-Gault formula).
- Left ventricular ejection fraction > 50% or above the Institutional Lower Limit of Normal (LLN), whichever is lower, determined by echocardiogram.
What rules you out
- Persistent clinically significant non-hematological toxicity related to previous treatments. The presence of alopecia and NCI-CTC grade <2 symptomatic peripheral neuropathy is allowed.
- The patient is known to be human immunodeficiency virus (HIV) positive, unless the patient is on antiviral therapy with HIV RNA levels <50 copies/mL; Hepatitis B surface antigen-positive or active hepatitis C infection, unless treated with undetectable hepatitis B DNA or hepatitis C RNA levels; or active CMV infection (IgM positive).
- Concomitant anti-tumor therapy within 14 days prior to Day 1 of Cycle 1.
- Prior allogeneic transplantation in the last 3 months or currently active GVHD with immunosuppressive treatment
- Limitation of the patient’s ability to comply with the treatment or follow-up protocol.
- If a COVID-19 vaccine is administered, it should be done >72 hours prior to study treatment initiation or after the completion of the dose-limiting toxicity (DLT) period (if patient is participating in the dose-escalation phase”).
- Pregnant or lactating women; men and women of reproductive potential who are not using effective contraceptive methods (combined hormonal contraception associated with inhibition of ovulation; progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinenence).
- History of any other neoplastic disease in the last five years (except basal cell carcinoma, skin epithelioma or carcinoma in situ of any site)
- History of clinically significant hypotension.
- History of clinically significant allergic or hyper-sensitivity reactions.
- History or known clinically significant vascular disease or known high risk of vascular disease (as assessed by the treating physician) including (but not limited to): - Thromboembolism - Peripheral arterial disease - Vasculitis
- Other relevant diseases or adverse clinical conditions: - Congestive heart failure or angina pectoris, myocardial infarction within 12 months before inclusion in the study. - Uncontrolled arterial hypertension or cardiac arrhythmias (i.e., requiring a change in medication within the last 3 months or hospital admission within the past 6 months). - History of significant neurological or psychiatric disorders
- Clinically significant or active infection.
- Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis)
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.